Issue: May 25, 2019
February 19, 2019
1 min read
Save

FDA clears liquid biopsy test to monitor response to chronic myeloid leukemia treatment

Issue: May 25, 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA cleared a liquid biopsy test designed to precisely and reproducibly monitor molecular response to treatment among patients with chronic myeloid leukemia.

The QXDx AutoDG ddPCR System (Bio-Rad Laboratories) — which uses Bio-Rad’s Droplet Digital polymerase chain reaction (PCR) technology — and the QXDx BCR-ABL %IS Kit are the first digital PCR products to receive FDA clearance.

The QXDx AutoDG ddPCR System is designed to be flexible, allowing users to run either FDA-cleared in vitro diagnostic tests or lab-developed tests on the platform.

“Bio-Rad is proud to announce our first FDA-cleared liquid biopsy test in oncology,” Annette Tumolo, executive vice president and president of Life Science Group at Bio-Rad Laboratories, said in a company-issued press release. “The QXDx AutoDG ddPCR System and QXDx BCR-ABL %IS Kit represent the first-ever digital PCR solution that can monitor and directly quantitate the molecular response of patients with chronic myeloid leukemia under tyrosine kinase inhibitor therapy.”